CurrentNeighborhood Health Plan of Rhode IslandPolicy 1770-A

Vigabatrin (Sabril, Vigadrone, Vigafyde, Vigpoder) coverage

Defines medical necessity and authorization durations for vigabatrin products for infantile spasms and refractory complex partial (focal) seizures for members of Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVigabatrin (Sabril, Vigadrone, Vigafyde, Vigpoder) coverage

Policy CodePolicy 1770-A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionSubmit prior authorization with specified authorization duration and documentation of inadequate response to required prior therapies where applicable.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4 wksinitial authorization duration for IESS

3 mosinitial authorization duration when prior treatments failed

6–12 mosauthorization durations for continuation of vigabatrin with benefit

1 mo–<2 yrinfantile spasms monotherapy age window

≥2 yradjunctive therapy age for complex partial seizures

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Vigabatrin

Initial therapy — Infantile spasms

Covered when ALL of the following are met

Infantile spasms initial: Diagnosis of infantile spasms (infantile epileptic spasms syndrome, IESS)

Infantile spasms initial: Patient age 1 month to less than 2 years

Infantile spasms initial: Provider documents that potential benefits of vigabatrin outweigh the potential risk of vision loss

Authorization of 4 weeks may be granted for treatment in members less than 2 years of age; vigabatrin is used as monotherapy for this indication.

Initial therapy — Refractory complex partial seizures

Covered when ALL of the following are met

Refractory complex partial seizures initial: Diagnosis of refractory complex partial (focal) seizures

Refractory complex partial seizures initial: Patient age 2 years or older

Refractory complex partial seizures initial: Inadequate response to at least two alternative treatments for complex partial seizures (documentation required)

Vigabatrin is indicated as adjunctive therapy and is not a first‑line agent; authorization of 3 months may be granted when criteria are met.

Continuation therapy

Covered when ALL of the following are met

Continuation therapy: Member has shown substantial clinical benefit from vigabatrin therapy (clinical documentation required)

Continuation therapy: Ongoing need for vigabatrin is documented by the provider

Authorization for continuation may be granted for 6 months (one statement) or 12 months (alternate statement) when substantial benefit is demonstrated.

All indications for vigabatrin products that are not expressly listed as covered (FDA‑approved indications and accepted compendial uses) are considered experimental/investigational and are not covered. Requests for such non‑listed indications may be denied.

Use of vigabatrin for indications other than infantile spasms (monotherapy in patients aged ≥1 month to <2 years when benefits outweigh vision‑loss risk) or refractory complex partial (focal) seizures (adjunctive therapy in patients ≥2 years who have failed multiple alternatives) is considered not medically necessary and is not covered.

Drug Products, Age Windows, and Codes

Covered drug productsmixedCovered

SABRIL	vigabatrin
VIGADRONE	vigabatrin
VIGAFYDE	vigabatrin
VIGPODER	vigabatrin
vigabatrin	vigabatrin

Age windows — infantile spasms and complex partial seizures

Infantile spasms (IESS)Age window: 1 month to <2 years (monotherapy indication)

Refractory complex partial (focal) seizuresAge window: ≥2 years (adjunctive therapy only)

Authorization note for IESSAuthorization of 4 weeks may be granted for treatment in members less than 2 years of age.

Prior Authorization, Step Therapy, and Authorization Durations

Prior Authorization

Required authorization durations

Prior authorization is required. Initial and continuation authorization durations vary by indication — see items for specific timeframes.

Infantile spasms (members < 2 years): Authorization of 4 weeks may be granted for treatment of infantile spasms (infantile epileptic spasms syndrome [IESS]).
Refractory complex partial seizures (adjunctive therapy, members ≥ 2 years): Authorization of 3 months may be granted when the member has had an inadequate response to at least two alternative treatments for complex partial seizures.
Continuation therapy for vigabatrin for complex partial seizures: Authorization of 6 months may be granted when the member has shown substantial clinical benefit from vigabatrin therapy.
Alternate continuation duration noted: Authorization of 12 months may be granted for members requesting vigabatrin for continuation of therapy when the member has shown substantial clinical benefit from vigabatrin therapy.

Background on Vigabatrin

Vigabatrin is an antiepileptic agent with FDA‑approved indications that include: infantile spasms — as monotherapy for pediatric patients aged 1 month to 2 years when the potential benefits outweigh the risk of vision loss; and refractory complex partial seizures — as adjunctive therapy in patients aged 2 years and older who have responded inadequately to several alternative treatments. Vigabatrin products are not indicated as first‑line therapy for complex partial seizures.

Key Definitions

Infantile spasms (IESS) — definition and usage window

DefinitionInfantile spasms (infantile epileptic spasms syndrome, IESS) — a seizure disorder in infants for which vigabatrin is indicated as monotherapy in pediatric patients 1 month to 2 years when potential benefits outweigh vision‑loss risk.

Usage windowMonotherapy indication applies to patients aged 1 month up to 2 years; authorization of 4 weeks may be granted for members less than 2 years of age.

Vision risk considerationUse is limited by potential risk of vision loss; treatment considered when benefits outweigh this risk.

Refractory complex partial (focal) seizures — definition and context for adjunctive therapy

DefinitionRefractory complex partial (focal) seizures — complex partial seizures in patients who have responded inadequately to several alternative treatments; vigabatrin indicated as adjunctive therapy.